Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial

BACKGROUND: Chronic obstructive pulmonary disease (COPD) clinical trials evaluating hard endpoints (mortality, hospitalized exacerbations) require a large number of subjects and prolonged observational periods. We hypothesized that a composite endpoint of respiratory outcomes (CERO) can help evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Celli, Bartolomé R., Decramer, Marc, Liu, Dacheng, Metzdorf, Norbert, Asijee, Guus M., Tashkin, Donald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855862/
https://www.ncbi.nlm.nih.gov/pubmed/27141828
http://dx.doi.org/10.1186/s12931-016-0361-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855862/
https://www.ncbi.nlm.nih.gov/pubmed/27141828
http://dx.doi.org/10.1186/s12931-016-0361-4

Ejemplares similares